Cornelis J M Melief

List of Publications by Year
in descending order

27	2,624	279798 23	526287 27
papers	citations	h-index	g-index

28	28	28	3282
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nature Reviews Cancer, 2008, 8, 351-360.	28.4	508
2	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Medicine, 1999, 5, 774-779.	30.7	439
3	Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein. Journal of Experimental Medicine, 1999, 190, 1033-1038.	8.5	305
4	Immature Dendritic Cells Acquire Cd8+Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cellâ€"Independent orâ€"Dependent Stimuli. Journal of Experimental Medicine, 2000, 192, 145-150.	8.5	173
5	Design and development of synthetic peptide vaccines: past, present and future. Expert Review of Vaccines, 2007, 6, 591-603.	4.4	130
6	Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes. International Journal of Cancer, 2001, 91, 612-618.	5.1	129
7	Expression of three extracellular matrix degradative enzymes in bladder cancer. International Journal of Cancer, 2001, 95, 295-301.	5.1	106
8	Reduced human leukocyte antigen expression in advancedâ€stage Ewing sarcoma: implications for immune recognition. Journal of Pathology, 2009, 218, 222-231.	4.5	87
9	Identification of three nonâ€VNTR MUC1â€derived HLAâ€A*0201â€restricted Tâ€cell epitopes that induce protective antiâ€tumor immunity in HLAâ€A2/Kbâ€transgenic mice. International Journal of Cancer, 2001, 91, 385-392.	5.1	85
10	Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLAâ€DQ and â€"DP as a restriction element. International Journal of Cancer, 2008, 122, 486-494.	5.1	74
11	Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. International Journal of Cancer, 2006, 118, 950-956.	5.1	59
12	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 2015, 6, 32228-32243.	1.8	58
13	CD80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic T-Cell Responses Directed at Patient Specific Minor Histocompatibility Antigens and Leukemia-Associated Antigens. Blood, 1998, 92, 1677-1684.	1.4	57
14	Addition of interferonâ€Î± to the p53â€SLPÂ® vaccine results in increased production of interferonâ€Î³ in vaccinated colorectal cancer patients: A phase I/II clinical trial. International Journal of Cancer, 2013, 132, 1581-1591.	5.1	50
15	Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. International Journal of Cancer, 2000, 87, 253-260.	5.1	44
16	The detection of circulating human papillomavirusâ€specific T cells is associated with improved survival of patients with deeply infiltrating tumors. International Journal of Cancer, 2011, 128, 379-389.	5.1	44
17	TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget, 2016, 7, 67087-67100.	1.8	43
18	Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. International Journal of Cancer, 2006, 118, 675-683.	5.1	41

#	Article	IF	Citations
19	Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. International Journal of Cancer, 2008, 123, 146-152.	5.1	36
20	Prediction of the immunogenic potential of frameshiftâ€mutated antigens in microsatellite instable cancer. International Journal of Cancer, 2008, 123, 838-845.	5.1	29
21	Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. International Journal of Cancer, 2003, 107, 425-433.	5.1	28
22	Local immunomodulation for cancer therapy: Providing treatment where needed. OncoImmunology, 2013, 2, e26493.	4.6	24
23	Competitionâ€Based Cellular Peptide Binding Assay for HLA Class I. Current Protocols in Immunology, 2004, 61, Unit 18.12.	3.6	23
24	Colorectal cancer vaccines in clinical trials. Expert Review of Vaccines, 2011, 10, 899-921.	4.4	23
25	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. OncoImmunology, 2018, 7, e1490855.	4.6	10
26	Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. Journal of General Virology, 2015, 96, 1478-1483.	2.9	10
27	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research, 2021, 9, 583-597.	3.4	9